메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Salajegheh Faranak (Clinical Research Development Unit, School of Medicine, Afzalipour Hospital, Kerman University of Medical Sciences, Kerman, Iran.) Rukerd Mohammad Rezaei Zadeh (Gastroenterology and Hepatology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran.) Nakhaie Mohsen (Gastroenterology and Hepatology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran.) Ghoreshi Zohreh-Al-Sadat (School of Medicine, Jiroft University of Medical Sciences, Jiroft, Iran.) Charostad Javad (Department of Microbiology, Faculty of Medicine, Shahid Sadoughi University of Medical Science, Yazd, Iran.) Arefinia Nasir (School of Medicine, Jiroft University of Medical Sciences, Jiroft, Iran.Bio Environmental Health Hazards Research Center, Jiroft University of Medical Sciences, Jiroft, Iran.)
저널정보
대한백신학회 Clinical and Experimental Vaccine Research Clinical and Experimental Vaccine Research Vol.13 No.2
발행연도
2024.4
수록면
83 - 90 (8page)
DOI
10.7774/cevr.2024.13.2.83

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
The emergence of coronavirus disease 2019 (COVID-19) vaccines has been a remarkable advancement. However, the efficacy, immunogenicity, and safety of these vaccines in in dividuals with liver cirrhosis require careful evaluation due to their compromised immune status and potential interactions with underlying liver disease. The present study aimed to evaluate the safety and efficacy of COVID-19 vaccines in liver cirrhosis patients. In the present study, we searched international databases, including Google Scholar, PubMed, Scopus, Embase, and Web of Science. The search strategy was carried out by using key words and MeSH (Medical Subject Headings) terms. STATA ver. 15.0 (Stata Corp., USA) was used to analyze the data statistically. The analysis was performed using the random effects model. We also used the chi-square test and I2 index to calculate heterogeneity among studies. For evaluating publication bias, Begg’s funnel plots and Egger’s tests were used. A total of 4,831 liver cirrhosis patients with COVID-19 were examined from 11 stud ies. The rate of hospitalization in the patients with liver cirrhosis was 17.6% (95% confi dence interval [CI], 9%–44%). The rate of fever in the patients with liver cirrhosis was 4.5% (95% CI, 0.9%–8.1%). The rate of positive neutralizing antibodies in the patients with liver cirrhosis was 82.5% (95% CI, 69.8%–95.1%). Also, the rates of seroconversion after the second vaccination in patients with liver cirrhosis and the control group were 96.6% (95% CI, 92.0%–99.0%), and 99.7% (95% CI, 99.0%–100.0%), respectively. COVID-19 vaccines have demonstrated promising efficacy, immunogenicity, and safety profiles in individuals with liver cirrhosis, providing crucial protection against COVID-19-related complications.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

최근 본 자료

전체보기

댓글(0)

0